Web of Science: 0 citas, Scopus: 0 citas, Google Scholar: citas
How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study
Santero, Marilina (Institut de Recerca Sant Pau)
Requeijo, Carolina (Institut de Recerca Sant Pau)
Quintana Ruiz, Maria Jesús (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Rodríguez, Dulce (Hospital Universitari Sant Joan de Reus (Tarragona))
Bottaro, David (Hospital Universitari Sant Joan de Reus (Tarragona))
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Farina, Natalie (Hospital de Donostia (Sant Sebastià, País Basc))
Blanco, Jesus Manuel (Hospital de Donostia (Sant Sebastià, País Basc))
Urreta-Barallobre, Iratxe (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
Punti, Laura (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
Bonfill, X. (Xavier) (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)

Fecha: 2024
Resumen: Aim: To assess the appropriateness of systemic oncological treatments (SOT) provided to patients diagnosed with advanced esophageal cancer (EC) across a group of participating hospitals. Methods: Multicenter, retrospective cohort study in five Spanish hospitals including newly confirmed advanced EC cases between July 1, 2014, and June 30, 2016, with a 5-year follow-up. Results: We identified 157 patients fulfilling the inclusion criteria (median age: 65 years, 85. 9% males). Most patients, 125 (79. 6%) were treated at least with one active treatment, and 33% received two or more lines of SOT. The 1-, 2- and 5-year overall survival rates were 30. 3% [95%CI: 23. 8, 38. 7], 14. 0% [95%CI: 9. 3, 21. 0], and 7. 1% [95% CI: 3. 8, 13. 1] respectively, and the median survival time 8 months (95% CI: 6, 19) for stages IIIb IIIc and 7 months (95% CI: 5, 9) for stage IV. Clinical stage, receiving more than one line of SOT, and treatment with radiotherapy accelerated the time to death (0. 4, 0. 9-, and 0. 8-times shorter survival respectively, p < 0. 05). Better performance status (ECOG < 2) extended survival time by 2. 2 times (p = 0. 04). Age < 65 years (OR 9. 4, 95% CI 3. 2, 31. 4, p < 0. 001), and being treated in one particular hospital (OR 0. 2, 95% CI 0. 0, 0. 8, p < 0. 01) were associated with the administration of two or more lines of SOT. Altogether, 18. 9% and 9. 0% of patients received chemotherapy in the last four and two weeks of life, respectively. Moreover, 2. 5% of patients were prescribed a new line of chemotherapy during the last month of life. The proportion of all patients who did not have access to palliative care reached 29. 3%, and among those who had access to it, 34. 2% initiated it in the last month of life. Conclusion: A high proportion of advanced EC patients receive many treatments not based on sound evidence and they do not benefit enough from palliative care services. The most accepted appropriateness indicators point out that some of the analyzed patients could have been overtreated. This study provides important insights into the quality of care provided to advanced EC, and furthermore, for giving valuable insight and opportunities for improvement.
Ayudas: Instituto de Salud Carlos III PI18/00034
Instituto de Salud Carlos III PI19/00335
Derechos: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Lengua: Anglès
Documento: Article ; recerca ; Versió publicada
Materia: Keywords Advanced esophageal cancer ; Systemic oncological treatment ; Appropriateness ; Palliative care
Publicado en: Clinical & translational oncology, 2024 , ISSN 1699-3055

DOI: 10.1007/s12094-024-03436-1
PMID: 38662169


11 p, 1.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Instituto de Investigación e Innovación Parc Taulí (I3PT)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Revisar > Revisió Biblioteca de Medicina
Artículos > Artículos de investigación
Artículos > Artículos publicados

 Registro creado el 2024-05-14, última modificación el 2024-07-03



   Favorit i Compartir